Carpenter Technology Corporation (ETR:XTY)
Germany · Delayed Price · Currency is EUR | Market Cap | 24.09B +126.9% |
| Revenue (ttm) | 2.73B +8.6% |
| Net Income | 463.73M +40.9% |
| EPS | 9.21 +41.8% |
| Shares Out | n/a |
| PE Ratio | 51.94 |
| Forward PE | 41.56 |
| Dividend | 0.80 (0.16%) |
| Ex-Dividend Date | Apr 28, 2026 |
| Volume | n/a |
| Open | 473.90 |
| Previous Close | 489.80 |
| Day's Range | 473.90 - 473.90 |
| 52-Week Range | 419.60 - 541.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Carpenter Technology
Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as metal powders and parts. It serves the aerospace, defense, medical, transportation, energy, industrial, and consumer mark... [Read more]
Financial Performance
In fiscal year 2026, Carpenter Technology's revenue was $3.12 billion, an increase of 8.59% compared to the previous year's $2.88 billion. Earnings were $529.80 million, an increase of 40.98%.
Financial numbers in USD Financial StatementsNews
Carpenter Technology price target lowered to $608 from $644 at KeyBanc
KeyBanc analyst Samuel McKinney lowered the firm’s price target on Carpenter Technology (CRS) to $608 from $644 and keeps an Overweight rating on the shares. Post the company’s Q4 results…
Carpenter Technology price target lowered to $689 from $722 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Carpenter Technology (CRS) to $689 from $722 and keeps a Buy rating on the shares.
Carpenter Technology price target lowered to $600 from $680 at Susquehanna
Susquehanna lowered the firm’s price target on Carpenter Technology (CRS) to $600 from $680 and keeps a Positive rating on the shares. The firm updated its model following Q4 results…
Carpenter Technology price target raised to $620 from $450 at BTIG
BTIG analyst Andre Madrid raised the firm’s price target on Carpenter Technology (CRS) to $620 from $450 and keeps a Buy rating on the shares after its Q4 earnings beat.
Carpenter Technology price target lowered to $700 from $705 at JPMorgan
JPMorgan lowered the firm’s price target on Carpenter Technology (CRS) to $700 from $705 and keeps an Overweight rating on the shares. The firm says the “healthy reset” with the…
Carpenter Technology Earnings Call Transcript: Q4 2026
Record quarterly and annual results were driven by strong demand, especially in aerospace and defense, with expanding margins and robust cash generation. FY 2027 guidance projects continued double-digit growth, supported by ongoing investments and a balanced capital allocation strategy.
Carpenter Technology Earnings release: Q4 2026
Carpenter Technology released its Q4 2026 earnings on July 30, 2026, summarizing the period's financial results.
Carpenter Technology Slides: Q4 2026
Carpenter Technology has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on July 30, 2026.
Carpenter Technology reports Q4 EPS $3.23, consensus $3.08
Reports Q4 revenue $851M, consensus $863.3M. “Carpenter Technology (CRS) delivered another record quarter, generating $206.9 million of operating income in the fourth quarter of fiscal year 2026,” sai...
Carpenter Technology Reports Fourth Quarter and Fiscal Year 2026 Results
Delivered Another Record Operating Income in Fourth Quarter Drove Adjusted Quarterly Operating Margins in Specialty Alloys Operations Segment to Record 37.8 Percent Fiscal Year 2026 Most Profitable Ye...
Steel company CEO, 59, dies ‘suddenly' just weeks after taking over top job
The newly appointed CEO of a $3 billion steel corporation died “suddenly and unexpectedly,” his company has announced.
Carpenter Technology announces passing of CEO Brian Malloy
Carpenter Technology (CRS) announced that Brian Malloy, the company’s president and CEO, passed away suddenly and unexpectedly on Friday, July 24. Tony Thene, the company’s executive chairman, has bee...
Carpenter Technology Announces the Passing of Brian Malloy
PHILADELPHIA, July 27, 2026 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) announced today that Brian Malloy, the Company's President and Chief Executive Officer, passed away suddenl...
Sales Gains Send Carpenter Technology Higher Before Earnings Report
Institutions push shares of Carpenter Technology Corporation (CRS) up 2,261% since 2005.
JPMorgan ups Carpenter target, places on ‘Negative Catalyst Watch’
JPMorgan analyst Bennett Moore raised the firm’s price target on Carpenter Technology (CRS) to $705 from $470 and keeps an Overweight rating on the shares. The firm attributes the recent…
Carpenter Technology price target raised to $650 from $470 at TD Cowen
TD Cowen analyst Gautam Khanna raised the firm’s price target on Carpenter Technology (CRS) to $650 from $470 and keeps a Buy rating on the shares. The firm adjusted targets…
Carpenter Technology price target raised to $680 from $495 at Susquehanna
Susquehanna raised the firm’s price target on Carpenter Technology (CRS) to $680 from $495 and keeps a Positive rating on the shares. The firm updated its model heading into 2Q…
Carpenter Technology Announces Conference Call and Webcast
PHILADELPHIA, July 01, 2026 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) plans to host a conference call and webcast on Thursday, July 30, 2026 at 10:00 a.m. ET to discuss the resu...
Supporting the Mission: Catholic Relief Services Chooses Adstra as a Fundraising Partner
PRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Adstra Nonprofit today announced a strategic partnership with Catholic Relief Services (CRS), one of the world's leading humanitarian organizations.
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon receives US FDA approval for expanded indications of TOFIDENCE, a biosimilar to ACTEMRA, in Cytokine Release Syndrome and Pediatric COVID-19.
Carpenter Technology Gains on Record Earnings, Profits
Institutional inflows push Carpenter Technology Corporation (CRS) shares up 1,894% since 2005.
Before SpaceX IPO, smart investors are buying these 3 stocks
SpaceX is expected to make its Nasdaq debut on June 12 in what could become the largest initial public offering in history. The company is targeting a valuation of about $1.75 trillion, with the propo...
Carpenter Technology price target raised to $470 from $450 at TD Cowen
TD Cowen raised the firm’s price target on Carpenter Technology (CRS) to $470 from $450 and keeps a Buy rating on the shares. The firm updated its model following recent…
Carpenter Technology benefits from high barriers to entry, Barron’s says
High demand for the company’s specialized alloys has contributed to Carpenter Technology (CRS) reporting record operating income last quarter, Barrons’ Todd Chanco writes in the publication’s Stock Pi...